← Research library

The efficacy of Semax in the treatment of patients at different stages of ischemic stroke

Comparison in people · 2018

What was studied
110 stroke patients; early/late rehabilitation groups with and without Semax
Main finding
The report links treatment and rehabilitation timing to plasma BDNF and functional outcomes.

Reported findings and study design

110 stroke patients: 43 men and 67 women, mean age 58.0 ± 9.7 years. Early rehabilitation 89 ± 9 days versus late 214 ± 22 days; each subdivided by Semax use.

Population or model 110 stroke patients; early/late rehabilitation groups with and without Semax

Dose, route and schedule

Semax: 6,000 micrograms/day in two ten-day courses separated by a 20-day interval during post-stroke rehabilitation. The route and within-day schedule are not specified in the indexed abstract.

Protocol source ↗ · Indexed publication abstract

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Semax regimen6,000 micrograms/dayTwo ten-day courses separated by a 20-day interval
BDNF and Barthel outcomesHigher BDNF and improved recovery reportedNo numerical between-group effect size in the abstract

Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.

Source for these results ↗ · Reviewed 2026-10-29

Study limitations and source details

Study limitations

  • Randomization and blinding are not established by the abstract.
  • BDNF association does not prove mediation; rehabilitation timing is a separate influence.
  • Disease-specific findings do not establish healthy-person enhancement.

Source details

Journal publication

Indexed citation and English abstract checked; full methods and risk of bias not appraised.

Sources checked

Citation

Human comparative studyEnglish abstract

E I Gusev, M Yu Martynov, E V Kostenko, L V Petrova, S N Bobyreva. The efficacy of Semax in the treatment of patients at different stages of ischemic stroke Zh Nevrol Psikhiatr Im S S Korsakova. 118(3 Vyp 2):61–68

Study source ↗ · DOI 10.17116/jnevro20181183261-68 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards